Silencing of ribophorin II reportedly facilitates the docetaxel-dependent apoptosis and cell growth inhibition of human breast cancer cells by reducing the N-linked glycosylation and membrane localization of P-glycoprotein. This evidence concerns the gene RPN2 and breast carcinoma.